Focusing on cell therapy, StemCyte-KY will officially list on Taiwan’s emerging stock market on December 5, with an underwriting price of NT$45 per share. During a pre-listing investor briefing on December 2, CEO Tong-Young Leestated that the company’s operations are driven by three key areas: cell-based new drugs, cell supply, and cell services. The company plans to deepen its presence in the U.S., expand into Europe, Asia, and the Middle East through distributors, and actively develop applications in the field of anti-aging to accelerate business growth.

Lee explained that unlike domestic cord blood companies, StemCyte is Taiwan’s only cell therapy company with both private and public cord blood banks. It is also the world’s first cell therapy company to receive FDA approval for a cord blood-based cell therapy drug. Its public cord blood bank is the company’s greatest asset, enabling the development of cell-based new drugs, cell supply, and cell services.

The development of cell-based new drugs and the cell supply business are beyond the scope of traditional private storage companies, as privately stored cord blood belongs to customers. StemCyte, on the other hand, can freely utilize its resources to develop new drugs and conduct clinical trials. For the cell supply business, the company provides FDA-compliant raw materials to its clients, which is a core focus for global market expansion. While its cell service offerings are similar to competitors, StemCyte is the only provider operating under FDA standards, justifying its higher pricing.

StemCyte is also the only private-public cord blood bank in Taiwan and one of only two in the U.S., where other public banks are run by NGOs. The company’s public cord blood bank holds 36,000 units, ranking as the largest private-public cord blood bank in the world. Lee highlighted that the ability to match cord blood for transplantation depends on inventory size: with 10,000 units, the matching rate is about 20%; with 20,000 units, it increases to 40-50%; and with 30,000 units, it reaches 80%. StemCyte has achieved a matching rate exceeding 95%, which is exceptionally valuable.

StemCyte is also the world’s first company to secure FDA approval for a cord blood-based cell therapy drug. Its product RegeneCyte is approved for 80 indications, including 16 cancers, 17 metabolic diseases, 21 hematological diseases, and 26 immune disorders, with over 2,300 successful cases worldwide. The company anticipates significant therapeutic impact beyond the scope of a single drug approval.

In addition to expanding in the U.S., StemCyte is targeting Europe, Asia, and the Middle East through distributors while actively exploring anti-aging applications.

Regarding the development of new indications, the company is progressing in areas such as:

• Long COVID, where Phase II clinical trials are underway in the U.S., supported by an FDA designation as a Regenerative Medicine Advanced Therapy (RMAT). Initial clinical results suggest potential for alleviating chronic fatigue, with future applications in chronic fatigue syndrome, aging-related diseases, and other long-term health conditions.
• Acute ischemic stroke, where clinical trials have demonstrated safety and efficacy, extending the treatment window from the conventional 4.5 hours to 9 days, offering greater opportunities for patient intervention.

In the area of cell supply, StemCyte’s large-scale public cord blood bank provides off-the-shelf availability, making it an attractive partner for CDMO, CRO, and cell therapy startups worldwide. In terms of cell services, the company’s FDA-approved status provides a significant competitive advantage in the global cell service industry, contributing to stable and long-term revenue.

With its strong position in the cell therapy field and ongoing expansion efforts, StemCyte aims to achieve sustainable growth while delivering innovative solutions to patients globally.

Resource: 永笙-KY 12月5日興櫃掛牌，射細胞三箭推動營運高速成長